Master Advanced Drug Designing: Traditional and In Silico in 4 weeks through hands-on, project-based online training with DSTC.
Drug Designing: Traditional and In Silico program offer a comprehensive exploration of the multifaceted process of drug discovery and development. These program blend traditional methods of drug design, involving chemical synthesis and experimental testing, with state-of-the-art computational approaches. Students delve into fundamental concepts of medicinal chemistry, pharmacology, and molecular biology, gaining insight into the principles governing drug-target interactions and structure-activity relationships. Every participant receives a verified e-Certificate and e-Marksheet from the Deep Science & Technology Consortium.
Drug Designing: Traditional and In Silico program offer a comprehensive exploration of the multifaceted process of drug discovery and development. These program blend traditional methods of drug design, involving chemical synthesis and experimental testing, with state-of-the-art computational approaches. Students delve into fundamental concepts of medicinal chemistry, pharmacology, and molecular biology, gaining insight into the principles governing drug-target interactions and structure-activity relationships.
1. Put biotechnology techniques to work on real datasets and case studies.
2. Assemble a documented case study that evidences your applied capability.
β’ Master's and senior undergraduate students specializing in biotechnology
β’ R&D engineers and working professionals applying biotechnology in industry
β’ Academics and educators building research or teaching capacity in biotechnology
β’ Tangible, reproducible biotechnology work to show supervisors or employers.
β’ A verified e-Certificate of competency and e-Marksheet from the Deep Science & Technology Consortium.
β’ Structure-activity relationships and bioisosteric replacement
β’ Lipinski and beyond: property-based design and ligand efficiency metrics
β’ Hit, lead and candidate stages and the decisions at each gate
β’ Target preparation, protonation states and binding-site definition
β’ Molecular docking, scoring function limitations and pose plausibility
β’ Structure-based optimisation guided by interaction analysis
β’ Pharmacophore modelling and shape-based screening
β’ QSAR with a defined applicability domain
β’ Similarity searching and scaffold hopping
β’ Molecular dynamics for stability and induced fit
β’ Binding free energy estimation and its cost-accuracy trade-off
β’ Interpreting simulation results without overclaiming
β’ ADMET prediction and the endpoints where models remain unreliable
β’ Toxicity alerts, off-target liabilities and hERG risk
β’ Why compounds fail late, and what earlier analysis could have caught
| Parameter | Requirement |
|---|---|
| Covered Tool / Platform | AutoDock Vina |
| Covered Tool / Platform | PyRx |
| Covered Tool / Platform | SchrΓΆdinger Suite |
| Covered Tool / Platform | GROMACS |
| Covered Tool / Platform | ChemDraw |
| Covered Tool / Platform | Discovery Studio |
| Covered Tool / Platform | ADMET Predictor |
Based on 0 scholar submissions
No verified reviews published yet. Be the first to share your academic experience.
Your rating will help prospective scholars. Ratings below 3 stars are routed privately to the faculty mentor for immediate response.